Correction: In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli (Antimicrobial Agents and Chemotherapy (2018) 62:8 (e00533-18) DOI: 10.1128/AAC.02576-17)

Suzannah M. Schmidt-Malan, Avisya J. Mishra, Ammara Mushtaq, Cassandra L. Brinkman, Robin Patel

Research output: Contribution to journalComment/debate


Isolate IDRL-10579 in Supplemental Table S2 is Pseudomonas aeruginosa but was mistakenly reported as Klebsiella pneumoniae; the isolate should be listed in Table S2 under P. aeruginosa containing a KPC genetic resistance mechanism. Accordingly, in the 1st paragraph of Materials and Methods, of the 177 isolates which are carbapenemase positive, 118 (not 119) are K. pneumoniae and 5 (not 4) are P. aeruginosa. Also, in Supplemental Table S4, there are 85 (not 86) isolates which are K. pneumoniae complex and 2 (not 1) isolates which are P. aeruginosa. Revised versions of these two supplemental tables have been posted online. In addition, the KPC gene-positive section of Table 2 has been revised as shown below due to an error in the cumulative MIC results. Accordingly, in the Results section, in the 1st paragraph of “Carbapenemase gene-positive isolates,” 3% (not 5%) of the KPC-positive isolates were susceptible to imipenem, 2% (not 3%) were susceptible to cefepime, 1% (not 2%) were susceptible to ceftriaxone, and 3% (not 4%) were susceptible to ceftolozane-tazobactam. In the 3rd paragraph of the Discussion section, 95% (not 93%) of the KPC-positive isolates were resistant to imipenem alone.

Original languageEnglish (US)
Article numbere02563-18
JournalAntimicrobial Agents and Chemotherapy
Issue number2
StatePublished - Feb 1 2019


ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this